NANOGEN AKTUELL - 500 Beiträge pro Seite

[Kipferl]

hallo zusammen

da meiner ansicht nach es etwas unübersichtlich im nanogen board zugeht dachte ich ich mach einen thread auf
wo wir wirklich gezielt die meldungen und eine aktuelle diskussion führen könnten

möchte alle die daran interressiert sind hier fakten über ngen zusammen zutragen und eventuell daten zu sammeln die
sich mit dem biochipsektor zu tun haben

die jüngsten meldungen von nanogen lassen ja mal auf ein ende der talfahrt schliessen





und nun noch die letzten beiden meldungen auf yahoo


Monday October 30, 11:21 am Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Hitachi Ships Nanogen System to Children`s Hospital of Tokyo

SAN DIEGO, Oct. 30 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today the shipment of a NanoChip(TM) instrument system to
National Children`s Hospital of Tokyo by Nissei Sangyo Inc., a distribution company of Hitachi, Ltd.

National Children`s Hospital represents the first customer to be served under Nanogen and Hitachi`s distribution agreement for Japan. The NanoChip system is
intended for use in the development of clinically relevant single nucleotide polymorphism (SNP) based tests for diagnosing and determining appropriate treatment for
childhood asthma/allergy patients.

Howard Birndorf, Nanogen`s Chairman and CEO, commented, ``We are quite pleased to have begun serving the Japanese market with our partner Nissei Sangyo.
National Children`s Hospital represents an important step by Nissei Sangyo in their process of methodically building a presence in the attractive Japanese clinical
research market. The National Children`s Hospital shipment also demonstrates that the clinical research market is a worldwide opportunity, as researchers in various
geographic regions seek to accelerate the introduction of clinically relevant tests into the patient care process.``

Hitachi, Ltd., headquartered in Tokyo, Japan, is one of the world`s leading global electronics companies, with fiscal 1999 (ended March 31, 2000) consolidated
sales of 8,001 billion yen ($75.5 billion*). The company manufactures and markets a wide range of products, including computers, semiconductors, consumer
products and power and industrial equipment. Scientific instrumentation is developed and manufactured through its Instrument Group based in Tokyo, Japan with a
principle factory in Hitachinaka City. Hitachi has been a leading supplier of instrumentation for research applications in highly regulated markets such as clinical
diagnostics and medical instrumentation. For more information on Hitachi, Ltd., please visit the Hitachi Web site at http://www.hitachi.co.jp.
(At an exchange rate of 106 yen to the dollar.)

Nissei Sangyo Co. Ltd., headquartered in Tokyo, Japan was established in 1947 as a trading company within Hitachi Group. Nissei covers extensive business areas
from Electronics and Informatics to Scientific Instruments. In fiscal 1999 (ended March 31, 2000), Nissei had consolidated sales of over 725 billion yen ($6.8
billion). Nissei is the exclusive sales representative for Hitachi scientific instruments worldwide. For more information concerning Nissei Sangyo Co., Ltd., please visit
Hitachi`s Internet web site at: http://www.Nisseisg.co.jp.

Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation and its NanoChip(TM) Cartridge to scientists and genomics laboratories,
setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate
their practical understanding and use of genetic information. The products introduced and under development are intended to provide quick and accurate analysis of
DNA, RNA and proteins, ``bridging`` the research and clinical diagnostic settings. For information on purchasing the NanoChip(TM) System in the U.S., please call
1-877-Nanogen or visit [e-mail] and in Europe, please call Peter Halkjaer-Knudsen, European Marketing Manager at 011-45-45-767202 or visit
[e-mail]. For additional product and company information, please visit Nanogen`s web site at http://www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the Company`s NanoChip(TM) System can be successfully commercialized, whether products under
development can be successfully developed and commercialized, whether results reported by the Company`s customers or partners can be replicated, whether the
Company`s products will be purchased by other customers and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and
elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking
statements.

Contact: Kieran T. Gallahue Page Sargisson, ext. 229
President/CFO Media
Nanogen, Inc. Noonan/Russo Communications
[phone] [phone]

SOURCE: Nanogen, Inc.




Tuesday October 31, 7:30 am Eastern Time

Press Release

SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia

Nanogen and The Children`s Hospital of Philadelphia Sign Collaboration
Agreement

- Focus on Development of High-Accuracy Genetic Tests -

SAN DIEGO, and PHILADELPHIA, Oct. 31 /PRNewswire/ -- Nanogen, Inc., (Nasdaq: NGEN - news) and The Children`s Hospital of Philadelphia announced
today that they will collaborate to develop high-accuracy genetic tests on Nanogen`s platform.

Paolo Fortina, M.D., Ph.D., an investigator at the Joseph Stokes, Jr. Research Institute of The Children`s Hospital of Philadelphia, recently presented successful
preliminary results from difficult genetic samples run on Nanogen`s system at the International Forum of Biochip Technologies in Beijing. The samples included DNA
insertions and deletions.

The Children`s Hospital of Philadelphia is considered a world leader in caring for children with diseases caused by a deletion of DNA on chromosome 22.
Chromosome 22q11.2 deletion syndrome is characterized by cardiac defects, cleft palate and feeding problems, among other things. Because physicians at
Children`s Hospital care for hundreds of children with this and other genetic diseases, access to fast and accurate genetic tests is an important component of the
Hospital`s clinical and research programs.

The object of the Nanogen/Children`s Hospital collaboration is to accelerate development of clinical diagnostics assays on Nanogen`s unique DNA microchips,
potentially leading toward higher quality, more timely diagnostic results. This is the first collaboration announced under Nanogen`s Development Site Program. Under
the agreement, Children`s Hospital will provide laboratory resources, collaborative expertise and product revenue in exchange for non-exclusive access to Nanogen`s
electronic DNA microarray technology. Nanogen and Children`s Hospital have also agreed to publish and present the validated study results. Children`s Hospital
intends to develop genetic tests using Nanogen`s NanoChip(TM) platform for use in the hospital`s clinical laboratories.

``I have been utilizing microarray technologies for several years,`` said Dr. Fortina, of the Hematology Division at Children`s Hospital and an associate professor of
Pediatrics at the University of Pennsylvania School of Medicine. ``When evaluating the NanoChip(TM) technology, Nanogen asked for us to submit our most
difficult samples to run as a performance demonstration. We gave them several different types, including Factor VII exon 8 amino acid 353, a decanucleotide
insertion/deletion at position *323 in the Factor VII promoter, MTHFR and Protein C SNP 1, 2 and 3. All samples were reported unambiguously and 100 percent
correct.`` Dr. Fortina concluded, ``We believe this technology will allow us to develop a variety of highly accurate genetic tests for the benefit of the healthcare
community.``

Howard Birndorf, Chairman and Chief Executive Officer of Nanogen commented: ``The Children`s Hospital of Pennsylvania has clearly demonstrated a desire to
improve patient care through the use of genetically-based diagnostic assays. We are pleased that they view the NanoChip(TM) technology as a key enabling
technology that may reduce the time-to-market and accuracy of a broad selection of reliable genetic tests. The objective of our relationship with the Children`s
Hospital is to develop new diagnostic tests that will assist medical doctors in the treatment of childhood diseases. The agreement with Children`s Hospital broadens
our development efforts by applying the NanoChip(TM) technology to the most challenging areas of genetic testing, clearly differentiating our product from other
systems.``

Microarray Technologies: New Tools for the Genomics and Post-Genomics Revolution

Human genomics, the study of the location and function of the tens of thousands of genes in every human cell, is increasingly the focus of medical and pharmaceutical
research. Understanding and decoding genomes is expected to accelerate the development of diagnostic procedures and of new drugs to detect, prevent and cure
disease.

Genomics is not limited to the study of human genomes. Other genomes, such as bacterial, viral, animal and plant genomes, hold commercial implications. As the
DNA sequencing of genomes are completed and more genes are functionally linked to biological processes or diseases, the tools used in laboratories must be
replaced or adapted to the very different standards required for post-genomics work. For example, while the priority in discovery genomics is very high throughput,
in post-genomics applications, such as certain DNA diagnostic assays, the priority is accuracy and versatility.

Nanogen and its customers have found the NanoChip(TM) system produces industry-leading accuracy for scoring genetic variations in patients, including single
nucleotide polymorphisms (SNPs), insertions, deletions and repeats. The no call rate on NanoChip(TM) systems has also been very low. Other techniques permit
high or very high throughput of either samples or SNPs, but most of these techniques do not work well with the other types of genetic variants. To date, the most
difficult samples, such as microvariants (or mutations within DNA repeat sequences), mutations that are adjacent to secondary DNA structures, repeat regions,
insertions, deletions, and scoring SNPs in genes found to have pseudogenes have been successfully analyzed on the NanoChip(TM) Molecular Biology Workstation
and its multi-use consumable, the NanoChip(TM) cartridge.

Under development at Nanogen are additional applications on the NanoChip(TM) platform, including high precision gene expression monitoring from multiple
experiments on the same NanoChip(TM). Gene expression currently is used primarily in research and in the near future is expected to be used routinely in clinical
diagnostics if a more reproducible system becomes available.

Nanogen`s Development Site Program

Nanogen has established the Development Site Program to actively collaborate with selected customers in strategically important market segments (including clinical
research, reference diagnostic laboratories, genomics, pharmaceutical, biotechnology and agrochemical companies) in the development of assays on the Nanogen
platform. Under these agreements, collaborating companies and institutions provide expertise and/or intellectual property in exchange for early access to Nanogen`s
technology. After applications are validated, the collaborating institutions may purchase the NanoChip(TM) Workstation and NanoChip(TM) cartridges for use in
their operations.

The Children`s Hospital of Philadelphia

Founded in 1855 as the nation`s first pediatric medical center, The Children`s Hospital of Philadelphia is a leader in patient care, education and research. The
Hospital is second in the United States among all children`s hospitals in total research funding from the National Institutes of Health.

Basic research in human genetics and clinical programs for children with genetic disease are major strengths at Children`s Hospital. Investigators from the Hospital,
led by Beverly S. Emanuel, Ph.D., chief of the division of Human Genetics and Molecular Biology, played an important role in the milestone announced last year by
the Human Genome Project, that chromosome 22 was the first human chromosome to be sequenced. Dr. Emanuel`s team also has analyzed areas of genetic
instability occurring in chromosome 22q11 deletion syndrome. Understanding the molecular mechanisms behind low-copy repeats will be important in an emerging
field of medicine called genomic disease-conditions that originate in the structure of the genome.

Dr. Paolo Fortina is a pediatrician and Director of the clinical Molecular Pathology section at Children`s Hospital. Dr. Fortina has an interest in developing
microdevice-based approaches for sample preparation, gene expression profiling and the detection of genetic mutations. In collaboration with the Department of
Pathology and Laboratory Medicine at The Hospital of the University of Pennsylvania, his group is developing a fully-integrated microdevice which will begin with a
drop of blood and end with a genetic profile of the individual. The device is intended to improve genetic testing while saving time and decreasing the costs of analysis.

Dr. Fortina`s current work is aimed at implementing protocols employing microarrays in diagnostics for common inheritable genetic diseases. He also is collaborating
in international studies aimed at discovering genes that regulate the switch from fetal to adult hemoglobin production as well as genes involved in inflammatory bowel
disease. In another project, Dr. Fortina and Dr. Eleanor Pollak, a pathologist at the University of Pennsylvania, are studying the potential use of a microdevice to
study genetic risk factors for pathological blood clotting associated with cardiovascular disease.

Nanogen, Inc.

Nanogen recently began marketing its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for
SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical
understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA
and proteins, ``bridging`` both the research and clinical diagnostic settings. For additional information please visit Nanogen`s web site at http://www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be or will be further successfully commercialized, whether
products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated,
whether the Company`s collaborations will continue to be funded and other risks and uncertainties discussed under the caption ``Factors That May Affect Results``
and elsewhere in the Company`s Form 10-K, as amended, for the year ended December 31, 1999, as amended, and subsequent reports filed with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these
forward-looking statements. The Company may, at its discretion, issue additional announcements regarding orders or sales of it NanoChip(TM) system as it deems
appropriate and as required by law.

Contact: Kieran T. Gallahue, President, CFO, of Nanogen, Inc., 858-410-4600; or Page Sargisson, Media, of Noonan-Russo Communications, 415-677-4455,
ext. 229, for Nanogen, Inc.

SOURCE: Nanogen, Inc. and The Children`s Hospital of Philadelphia



und die letzten qurtalszahlen






Tuesday October 31, 4:00 pm Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Nanogen Reports 2000 Third Quarter Results

SAN DIEGO, Oct. 31 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for the third quarter ended September 30,
2000.

Total revenues for the quarter ended September 30, 2000 were $3.5 million compared to $1.9 million for the same period in 1999. For the first nine months of
2000, total revenues were $8.2 million as compared to $6.1 million for the same period in 1999. Revenue recognized during the quarter and the nine months ended
September 30, 2000 and September 30, 1999 was earned in connection with sponsored research programs derived from the Company`s corporate alliances and
from contracts and grants with government agencies. In addition, $545,000 and $709,000 in revenue recognized during the quarter and the nine months ended
September 30, 2000, respectively, resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.

Total operating expenses for the third quarter of 2000 were $9.9 million, as compared to $7.6 million for the same period in 1999. For the first nine months of 2000,
total operating expenses were $24.3 million compared to $25.2 million for the same period in 1999. The increase in operating expenses for the third quarter of 2000
as compared to the same period in 1999 is primarily due to an increase in legal expenses related to enhancing Nanogen`s intellectual property portfolio and fees
related to patent litigation, as well as increased sales and marketing expenses as the Company expanded its sales and marketing organization. The Company
anticipates a continuation of these increased expenditures as the patent portfolio continues to increase, litigation continues and the NanoChip(TM) system launch
progresses. The decrease in operating expenses for the nine months ended September 30, 2000 as compared to the same period in 1999 is attributable primarily to
a reduction in spending internally and externally with engineering and prototype design vendors. These reductions are a result of the completion of the prototype
development phase and transition of the prototype to Hitachi, Ltd. for further development and manufacture of the Company`s initial commercial product, the
NanoChip(TM) Molecular Biology Workstation.

For the quarter ended September 30, 2000, the Company reported a net loss of $4.6 million or $0.22 per share, compared to a net loss of $5.2 million or $0.29
per share for the same period in 1999. For the first nine months of 2000, the Company reported a net loss of $12.4 million or $0.62 per share, compared to a net
loss of $18.6 million or $1.03 per share for the same period in 1999.

``Nanogen continued to execute extremely well in the third quarter, making progress in expanding our customer base and corporate partnerships,`` stated Howard
Birndorf, Chairman and CEO of Nanogen. ``As our intention is to establish the NanoChip(TM) system as the standard for performing genetic-based clinical
research studies, our growth is encouraging. It has become increasingly clear to us that this market segment will be the gate-keeper to the long term use of genetic
information in the clinical setting. It is our intention over the coming year to establish a leadership position in this growing and attractive market segment by targeting
high value, high profile customers.`` Birndorf continued, ``By the completion of the third quarter, we had sold seven NanoChip(TM) systems, six directly to end users
and one through a funded research agreement. Our customer list in the US and Europe now includes the Mayo Clinic, the National Cancer Institute, Egea
Biosciences, Aventis and SKW Biosciences. The additional sale recorded through funded research was also to Aventis as part of our collaboration to develop gene
expression applications for the NanoChip(TM) system. Since the end of the third quarter we have continued our progress, placing research instruments at the
Children`s Hospital of Pennsylvania and The Children`s Hospital of Tokyo. Customers will now be using the NanoChip(TM) system for diverse applications in
clinical research, including cancer, infectious disease and pharmacogenomic applications.``

``We also made substantial progress on the corporate partnership front. A critical challenge in achieving Nanogen`s goal of becoming a key player in the clinical
research and eventually the clinical diagnostics industries is the continued evolution of the NanoChip(TM) instrument platforms. To that end, we have expanded and
extended our relationship with Hitachi, securing a ten-year relationship for the development and manufacture of instrument systems. Hitachi will bear the primary
expense of developing future generations of instruments, while Nanogen will focus on our core competency of the NanoChip(TM) cartridge and applications
development. Hitachi`s long history of serving both the research market and the government regulated clinical diagnostic market molds well with Nanogen`s capability
of serving as a unique bridge between these two valuable markets, potentially accelerating the healthcare system`s ability to use genetic information in practical,
patient care applications. Hitachi also invested two million dollars in Nanogen equity, purchasing 74,590 shares at $26.813 per share, the fair market value on the
effective date of the collaboration agreement,`` Birndorf continued. ``Nanogen also completed the realignment of the Becton Dickinson (BD) joint venture. We
expanded our licensing rights to BD`s proprietary amplification technique, Strand Displacement Amplification (SDA). We have secured commercialization rights to
the technologies developed by the partnership. We have established a mechanism for BD to review certain cancer-related genetic content which may be developed
or acquired by BD for appropriateness of delivering that content via Nanogen`s platforms. And perhaps most importantly, Nanogen has now regained full rights to
commercialize its products and technologies in the infectious disease diagnostics market, increasing our flexibility as we prepare to address the clinical diagnostics
market.``

During the third quarter, the company received two grants and extended its patent portfolio. Both the grants and the patent issued may benefit the development of
integrated, electronics-based sample to answer systems, an important element of Nanogen`s longer-term platform development strategy. The grants were awarded
by the U.S. Army and the Space and Naval Warfare Systems Center San Diego and provide continued funding for the development of Nanogen`s core
technologies.

Nanogen made substantial progress during the third quarter building the commercial infrastructure required to serve the clinical research market. The Company
announced the opening of its European sales office and the appointment of a European Managing Director. The sales, marketing and support team has expanded and
is expected to continue to expand aggressively throughout the remainder of 2000. In addition, Nanogen plans to initiate an awareness building campaign during the
fourth quarter of 2000, accelerating in early 2001.

``We are aggressively expanding our commercial efforts. Our focus in the coming year will be on establishing relationships with customers representing a broad
cross-section of clinical research that demonstrates the NanoChip`s(TM) core benefits -- flexibility, versatility, accuracy and cost effectiveness,`` commented Kieran
Gallahue, Nanogen`s President and Chief Financial Officer. ``We have already placed NanoChip(TM) systems with a range of customers, including customers in the
hospital, university, government, and pharmaceutical and food additives sectors. Customers are utilizing our electronics-based technology for performing SNP and
gene expression studies related to drug metabolism, childhood cancer, infectious diseases and others. Users have provided very positive assessments of our
technology by speaking at conferences from China to Philadelphia. We will measure our success in the coming year by our ability to establish a foundation that can
develop into market leadership in the clinical research market, a foundation evidenced by an expanding customer base and by a growing range of applications and
assays used and developed by customers. Our success in this early phase of commercialization has been very encouraging.``

Nanogen continued to evolve its organizational structure, adding skill sets critical to the next phase of growth. Kieran T. Gallahue, Nanogen`s Chief Financial Officer
and formerly Nanogen`s Vice President of Strategic Marketing, was appointed President in September. Dr. Regina Herzlinger, a recognized expert on the American
healthcare system and on management control, was recently added to the board of directors. Nanogen has stated its intention to continue the organizational evolution
process as the company fully transitions from a pre-product, early stage company to a successful commercial organization.

Birndorf concluded, ``I believe our results continue to speak for themselves. Our progress continues on track and I remain encouraged and confident that Nanogen
can establish itself as a leading company serving the targeted-genetic clinical research market.``

Nanogen recently began marketing its NanoChip(TM) system to scientists and genomics laboratories setting new standards for SNP scoring. In beta testing, the
NanoChip(TM) system has been shown to provide accuracy equal to or better than DNA sequencing and other methods for SNP confirmation. Unlike other
systems, the NanoChip(TM) system uses electronically accelerated hybridization under very low salt conditions, potentially avoiding problems with DNA
conformation and secondary structures, whereas most sequencing and primer extension technologies require high salt conditions. The NanoChip(TM) system allows
the user to array and analyze DNA on its NanoChip(TM) cartridges in user selected formats in a single day with walk-away automation. The NanoChip(TM) system
integrates advanced microelectronics and molecular biology into a platform technology with broad commercial applications in the fields of biomedical research,
genomics, medical diagnostics, genetic testing and drug discovery. The Company has established corporate alliances as part of its strategy to expand the applications
and accelerate the commercialization of products derived from its technology.

The company will hold its earnings conference call today at 4:30 p.m. EDT. To listen, visit http://www.videonewswire.com/NANOGEN/103100.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the patented inventions will or can be successfully incorporated into commercial products, whether the
Company`s pending litigation will be successful, whether we will sell additional products, whether the relationship with Hitachi and other corporate partners will
continue, whether the full amounts anticipated will be invested in the Hitachi collaboration, whether the Company`s products under development can be successfully
developed and commercialized, whether products will be purchased by additional customers, whether the currently anticipated instruments, applications and assays
will be developed, whether the Company can establish a leadership position in its target markets, whether the Company`s collaborations will continue to be funded
and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K as amended for the
year ended December 31, 1999 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the
date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: Nanogen, Inc.
Kieran T. Gallahue
President and Chief Financial Officer
858-410-4600

Noonan/Russo Communications
Page Sargisson (Media)
415-677-4455 (Ext. 229)

NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

Sept. 30, Dec. 31,
2000 1999
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $89,618 $41,021
Short-term investments 8,954 --
Receivables 2,650 1,641
Inventory 2,070


grüsse
K.

[Kipferl]

faule säcke

aber in nanotechnologie investieren weil nanogen = nanotech oder wie oder doch nicht


K.